A Two-Stage Decision Making Approach for Safety Studies

Area of Science:

• Pharmacovigilance and Drug Safety
• Biostatistics and Clinical Trial Design

Background:

• Traditional safety studies often use hypothesis testing for detecting safety signals or ruling out concerns, but non-significant results can be ambiguous.
• Misinterpreting non-significance as absence of risk is problematic, especially with low power or high variability in safety data.
• Existing frameworks may not adequately combine the objectives of detecting potential harm and confirming safety.

Purpose of the Study:

• To introduce a novel Two-Stage Decision-Making (TSDM) approach for safety studies to address interpretation issues with non-significant findings.
• To enhance the probability of reaching a definitive conclusion in safety assessments by integrating both signal detection and risk-ruling-out objectives.
• To provide a robust statistical framework for safety studies that improves decision-making clarity.

Main Methods:

• The TSDM approach is a ruling-out design incorporating an interim analysis.
• It applies both detecting and ruling-out criteria at interim and final stages using a pre-specified alpha spending function.
• The framework utilizes both directions of the confidence interval for decision-making at each analysis stage.

Main Results:

• The TSDM approach was assessed for operational type I error rate, overall study power, and probability of making a decision.
• Monte Carlo simulations were conducted to evaluate the approach's properties across various confidence interval outcome types.
• The study provides insights into sample size requirements and statistical interpretations for the TSDM design.

Conclusions:

• The proposed Two-Stage Decision-Making (TSDM) approach offers a unified framework for safety studies, improving the ability to detect safety signals and rule out concerns.
• This integrated design increases the likelihood of making a definite decision, thereby enhancing the reliability of safety assessments.
• The TSDM approach has significant implications for optimizing clinical trial design in drug safety evaluations.